(19)
(11) EP 2 298 811 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
18.02.2015 Bulletin 2015/08

(45) Mention of the grant of the patent:
26.11.2014 Bulletin 2014/48

(21) Application number: 10075518.0

(22) Date of filing: 16.10.2003
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
 C07K 16/24(2006.01)

(54)

Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors

Menschliche Anti-IFN-Gamma-neutralisierende Antikörper als selektive IFN-Gamma-Pfadhemmer

Anticorps humains à neutralisation anti-IFN-gamma en tant qu'inhibiteurs sélectifs de chemin IFN-gamma

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(30) Priority: 16.10.2002 US 419057
17.06.2003 US 479241

(43) Date of publication of application:
23.03.2011 Bulletin 2011/12

(62) Application number of the earlier application in accordance with Art. 76 EPC:
03777635.8 / 1578936

(73) Proprietors:
  • Amgen Inc.
    Thousand Oaks, CA 91320-1799 (US)
  • E. R. Squibb & Sons, L.L.C.
    Princeton, NJ 08540 (US)

(72) Inventors:
  • Welcher, Andrew A
    Ventura, CA 93001 (US)
  • Chute, Hilary, T
    Calabasas, CA 91302 (US)
  • Li Yue-Sheng
    Thousand Oaks, CA 91360 (US)
  • Huang, Haichun
    Fremont, CA 94538-5919 (US)

(74) Representative: Grünecker, Kinkeldey, Stockmair & Schwanhäusser 
Leopoldstrasse 4
80802 München
80802 München (DE)


(56) References cited: : 
WO-A2-99/09055
 US-B1- 6 329 511
   
  • LANDOLFI N F ET AL: "The integrity of the ball-and-socket joint between V and C domains is essential for complete activity of a humanized antibody", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 166, no. 3, 1 February 2001 (2001-02-01), pages 1748-1754, XP002959847, ISSN: 0022-1767
  • FIORENTINI S ET AL: "A partially humanized monoclonal antibody to human IFN-gamma inhibits cytokine effects both in vitro and in vivo", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, vol. 55, no. 3, March 2002 (2002-03), pages 284-292, XP002347393, ISSN: 0300-9475
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).